These results suggest that MSI2 promotes tumorigenic growth into mice spleen and BM in MCL xenograft in vivo models and support the concept that targeting MSI2 in vivo could have therapeutic efficacy in MCL. This evidence concerns the gene MSI2 and mantle cell lymphoma.